Cite
Dabigatran etexilate in people with atrial fibrillation: Has some benefits over warfarin, but evidence on long term efficacy and safety is lacking.
MLA
Raju, Nina C., and Graeme J. Hankey. “Dabigatran Etexilate in People with Atrial Fibrillation: Has Some Benefits over Warfarin, but Evidence on Long Term Efficacy and Safety Is Lacking.” BMJ: British Medical Journal (Overseas & Retired Doctors Edition), vol. 341, no. 7775, Oct. 2010, pp. 682–83. EBSCOhost, https://doi.org/10.1136/bmj.c3784.
APA
Raju, N. C., & Hankey, G. J. (2010). Dabigatran etexilate in people with atrial fibrillation: Has some benefits over warfarin, but evidence on long term efficacy and safety is lacking. BMJ: British Medical Journal (Overseas & Retired Doctors Edition), 341(7775), 682–683. https://doi.org/10.1136/bmj.c3784
Chicago
Raju, Nina C., and Graeme J. Hankey. 2010. “Dabigatran Etexilate in People with Atrial Fibrillation: Has Some Benefits over Warfarin, but Evidence on Long Term Efficacy and Safety Is Lacking.” BMJ: British Medical Journal (Overseas & Retired Doctors Edition) 341 (7775): 682–83. doi:10.1136/bmj.c3784.